Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
Meiji Scoops Up Marketing Rights for Mochida’s Epadel in Vietnam
Mochida Pharmaceutical and Meiji Seika Pharma said on April 6 that they have entered into a marketing agreement for Mochida’s high-purity ethyl icosapentate (EPA) agent Epadel S (ethyl icosapentate) in Vietnam. Under the terms of the deal, Mochida will award…
To read the full story
Related Article
- Epadel Launched in Vietnam: Mochida/Meiji
March 3, 2026
- Vietnam Clears Epadel for Import, Launch Planned via Partner: Mochida/Meiji
June 20, 2025
- Mochida, Meiji Expand Epadel Sales Collab to ASEAN, Taiwan
September 2, 2024
- Mochida, Meiji Adds China for Epadel Sales Collaboration
April 4, 2024
BUSINESS
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- Nipro Recalls Febuxostat after Finding Expired API Use at Another Plant
July 23, 2026
- Novo’s Koriyama Plant Achieves Net-Zero CO2 Emissions
July 23, 2026
- Sanofi Files Dupixent for AFRS in Japan
July 23, 2026
- Nippon Shinyaku Licenses NS-025 to US Biotech Aquelys
July 23, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…